SpringWorks Therapeutics Awaits European Commission Decision on Approval of Nirogacestat for Desmoid Tumors, Expected Q3 2025

Reuters06-20

SpringWorks <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Awaits European Commission Decision on Approval of Nirogacestat for Desmoid Tumors, Expected Q3 2025

STAMFORD, Conn., June 20, 2025 - SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company, announced that the European Medicine Agency's $(EMA)$ Committee for Medicinal Products for Human Use $(CHMP)$ has adopted a positive opinion recommending the approval of nirogacestat. This oral gamma secretase inhibitor is proposed as a monotherapy for adults with progressing desmoid tumors requiring systemic treatment. If approved, nirogacestat will be the first and only therapy with marketing authorization in the EU for this condition. The European Commission is expected to make a final decision in the third quarter of 2025. The recommendation was based on the results from the Phase 3 DeFi trial, which demonstrated significant improvements in progression-free survival and patient-reported outcomes.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SpringWorks Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9471833-en) on June 20, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2544912477?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-20 20:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2544912477","market":"nz","top_or_hot":-1,"title":"SpringWorks Therapeutics Awaits European Commission Decision on Approval of Nirogacestat for Desmoid Tumors, Expected Q3 2025","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      SpringWorks <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Awaits European Commission Decision on Approval of Nirogacestat for Desmoid Tumors, Expected Q3 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        STAMFORD, Conn., June 20, 2025 - <a href=\"https://laohu8.com/S/SWTX\">SpringWorks Therapeutics, Inc.</a> (Nasdaq: SWTX), a commercial-stage biopharmaceutical company, announced that the European Medicine Agency's <a href=\"https://laohu8.com/S/EMA\">$(EMA)$</a> Committee for Medicinal Products for Human Use <a href=\"https://laohu8.com/S/CHMP\">$(CHMP)$</a> has adopted a positive opinion recommending the approval of nirogacestat. This oral gamma secretase inhibitor is proposed as a monotherapy for adults with progressing desmoid tumors requiring systemic treatment. If approved, nirogacestat will be the first and only therapy with marketing authorization in the EU for this condition. The European Commission is expected to make a final decision in the third quarter of 2025. The recommendation was based on the results from the Phase 3 DeFi trial, which demonstrated significant improvements in progression-free survival and patient-reported outcomes.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SpringWorks Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9471833-en) on June 20, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>SpringWorks Therapeutics Awaits European Commission Decision on Approval of Nirogacestat for Desmoid Tumors, Expected Q3 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSpringWorks Therapeutics Awaits European Commission Decision on Approval of Nirogacestat for Desmoid Tumors, Expected Q3 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-20 20:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      SpringWorks <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Awaits European Commission Decision on Approval of Nirogacestat for Desmoid Tumors, Expected Q3 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        STAMFORD, Conn., June 20, 2025 - <a href=\"https://laohu8.com/S/SWTX\">SpringWorks Therapeutics, Inc.</a> (Nasdaq: SWTX), a commercial-stage biopharmaceutical company, announced that the European Medicine Agency's <a href=\"https://laohu8.com/S/EMA\">$(EMA)$</a> Committee for Medicinal Products for Human Use <a href=\"https://laohu8.com/S/CHMP\">$(CHMP)$</a> has adopted a positive opinion recommending the approval of nirogacestat. This oral gamma secretase inhibitor is proposed as a monotherapy for adults with progressing desmoid tumors requiring systemic treatment. If approved, nirogacestat will be the first and only therapy with marketing authorization in the EU for this condition. The European Commission is expected to make a final decision in the third quarter of 2025. The recommendation was based on the results from the Phase 3 DeFi trial, which demonstrated significant improvements in progression-free survival and patient-reported outcomes.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SpringWorks Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9471833-en) on June 20, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SWTX","symbol_name":"SpringWorks Therapeutics, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250620:nNDL2NT4rN:1","article_id":"2544912477","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2544912477","pubTimestamp":1750420863,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"SpringWorks Therapeutics Awaits European Commission Decision on Approval of Nirogacestat for Desmoid Tumors, Expected Q3 2025. STAMFORD, Conn., June 20, 2025 - SpringWorks Therapeutics, Inc. , a commercial-stage biopharmaceutical company, announced that the European Medicine Agency's  Committee for Medicinal Products for Human Use  has adopted a positive opinion recommending the approval of nirogacestat. This oral gamma secretase inhibitor is proposed as a monotherapy for adults with progressing desmoid tumors requiring systemic treatment. If approved, nirogacestat will be the first and only therapy with marketing authorization in the EU for this condition. The European Commission is expected to make a final decision in the third quarter of 2025. The recommendation was based on the results from the Phase 3 DeFi trial, which demonstrated significant improvements in progression-free survival and patient-reported outcomes.Disclaimer: This news brief was created by Public Technologies  usi","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SWTX":"SpringWorks Therapeutics, Inc.","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","BK4139":"生物科技","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","NDAQ":"纳斯达克OMX交易所","BK4585":"ETF&股票定投概念","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","BK4588":"碎股","BK4112":"金融交易所和数据","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD"},"translate_title":"SpringWorks Therapeutics等待欧盟委员会批准Nirogacestat治疗硬纤维瘤的决定，预计2025年第三季度","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SWTX":0.9,"NDAQ":0.9},"content_text":"SpringWorks Therapeutics Awaits European Commission Decision on Approval of Nirogacestat for Desmoid Tumors, Expected Q3 2025\n    \n\n        STAMFORD, Conn., June 20, 2025 - SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company, announced that the European Medicine Agency's $(EMA)$ Committee for Medicinal Products for Human Use $(CHMP)$ has adopted a positive opinion recommending the approval of nirogacestat. This oral gamma secretase inhibitor is proposed as a monotherapy for adults with progressing desmoid tumors requiring systemic treatment. If approved, nirogacestat will be the first and only therapy with marketing authorization in the EU for this condition. The European Commission is expected to make a final decision in the third quarter of 2025. The recommendation was based on the results from the Phase 3 DeFi trial, which demonstrated significant improvements in progression-free survival and patient-reported outcomes.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SpringWorks Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9471833-en) on June 20, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2544912477","isCrawlerRequest":true}